Credit Suisse took the IMCD share off its sales list on Monday now that the price is approaching the price target, after the first quarter figures. The advice went down to neutral, but the price target went up, from 115.00 to 120.00 euro. Credit Suisse’s profit estimates are less than 3 percent of the consensus for the next three years, the analysts noted. Sector partner Brenntag is now found more attractive in chemical distribution, as is DKSH, which is relatively cheaper. Credit Suisse believes that IMCD will continue to gain market share with an autonomous annual Composite profit growth of around 11 percent in the period 2022 to 2024. There may be additional profit from acquisitions. The IMCD share stood unchanged at 125.80 euros on Monday.